ALK and non-small cell lung carcinoma: The rearrangement of the anaplastic lymphoma kinase (ALK) gene was a crucial driver genetic event, identified in 3–7% of NSCLC patients, and first-line ALK-tyrosine kinase inhibitors (TKIs) have markedly improved the patients’ survival benefit compared to conventional chemotherapy.